2.78
+0.16(+6.11%)
Currency In USD
Address
80 Guest Street
Boston, MA 02135
United States of America
Phone
617 500 8099
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
April 05, 2021
| Name | Title | Pay | Year Born |
| Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer & Vice Chairman | 994,800 | 1961 |
| Mr. Barry Shin J.D., M.B.A. | Chief Financial Officer | 406,256 | 1972 |
| Mr. Jonathan E. Anderman J.D. | Senior Vice President, General Counsel & Corporate Secretary | 541,620 | N/A |
| Ms. Vered Bisker-Leib MBA, Ph.D. | Advisor | 1.53M | 1971 |
| Mr. Neil L. Lerner CPA | Senior Vice President & Chief Accounting Officer | 0 | 1967 |
| Ms. Karin Herrera B.A. | Senior Vice President & Head of Clinical Operations | 0 | N/A |
| Anna Gifford | Communications Manager | 0 | N/A |
| Dr. James Kranz Ph.D. | Vice President and Head of Chemistry Manufacturing & Controls | 0 | N/A |
| Dr. Minori Rosales M.D., Ph.D. | Senior Vice President & Head of Clinical Development | 0 | 1963 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.